Diabetes alters the myocardial cAMP-protein kinase cascade system

Insights

Alloxan-induced diabetes impairs the heart's cyclic adenosine monophosphate (cAMP) system response to isoproterenol. Diabetic rat hearts show altered amplification cascade gain, suggesting a parallel regulatory pathway in beta-adrenergic signaling.

Area of Science:

  • Cardiovascular Physiology
  • Endocrinology
  • Biochemistry

Background:

  • Diabetes mellitus is a metabolic disorder with significant cardiovascular complications.
  • The cyclic adenosine monophosphate (cAMP) cascade plays a crucial role in cardiac function and beta-adrenergic signaling.
  • Alloxan-induced diabetes in rats is a common model to study diabetes-related physiological changes.

Purpose of the Study:

  • To investigate the impact of alloxan-induced diabetes on the cAMP cascade system in isolated perfused working rat hearts.
  • To determine how diabetes affects basal and stimulated levels of cAMP, cGMP, and related enzyme activities.
  • To analyze the relationship between cAMP, protein kinase, phosphorylase activation, and left ventricular pressure (LVP) in diabetic hearts.

Main Methods:

  • Utilized an isolated perfused working rat heart preparation.
  • Induced diabetes using alloxan.
  • Measured basal and isoproterenol-stimulated cAMP and cGMP content.
  • Assessed protein kinase and phosphorylase activities.
  • Analyzed the relationships between signaling molecules and cardiac function (LVP).

Main Results:

  • Diabetes did not alter basal cAMP, cGMP, protein kinase, or phosphorylase activities.
  • Isoproterenol-induced changes in cAMP content and protein kinase activity were reduced by 50% in diabetic hearts.
  • Phosphorylase activation and increased LVP in response to isoproterenol were unaltered by diabetes.
  • Diabetic hearts exhibited an increased gain in the amplification cascade from protein kinase to phosphorylase activation and LVP.
  • Insulin administration in vivo diminished this increased gain.

Conclusions:

  • Alloxan-induced diabetes impairs the heart's ability to accumulate cAMP in response to beta-adrenergic stimulation.
  • Diabetes alters the gain of the amplification cascade subsequent to protein kinase activation.
  • This alteration may indicate the unmasking of a parallel regulatory pathway in beta-adrenergic regulation of cardiac function.

Related Concept Videos

cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Diabetic Ketoacidosis ll: Pathophysiology01:22

Diabetic Ketoacidosis ll: Pathophysiology

Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration occur due to afferent arteriolar...